Resveratrol Reduces Prostate Cancer Growth and Metastasis by Inhibiting the Akt/MicroRNA-21 Pathway

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Sheth, Sandeep ^a   Jajoo, Sarvesh ^a   Kaur, Tejbeer ^a   Mukherjea, Debashree ^a   Sheehan, Kelly ^a   Rybak, Leonard P ^a   Ramkumar, Vickram ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN RECEPTOR; MASPIN; MICRORNA 21; OLIGONUCLEOTIDE; PROGRAMMED DEATH 4 RECEPTOR; PROTEIN KINASE B; RESVERATROL; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GENE CONTROL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MIR 21 GENE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; ENZYME INHIBITORS; ESTROGENS; FLOW CYTOMETRY; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, SCID; MICRORNAS; MORPHOLINES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING; STILBENES; WOUND HEALING;

EID: 84871318501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051655     Document Type: Article

References (57)

1. Khan N, Afaq F, Mukhtar H, (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510.
2. Fremont L, (2000) Biological effects of resveratrol. Life Sci 66: 663-673.
3. Maxwell S, Cruickshank A, Thorpe G, (1994) Red wine and antioxidant activity in serum. Lancet 344: 193-194.
4. Yu W, Fu YC, Wang W, (2011) Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113: 752-759.
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
6. Agarwal C, Sharma Y, Agarwal R, (2000) Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis. Mol Carcinog 28: 129-138.
7. Dorrie J, Gerauer H, Wachter Y, Zunino SJ, (2001) Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 61: 4731-4739.
8. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, et al. (2001) Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 496: 171-180.
9. Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, et al. (2007) Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28: 1946-1953.
10. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM, (2000) Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657-3667.
11. Levi F, Pasche C, Lucchini F, Ghidoni R, Ferraroni M, et al. (2005) Resveratrol and breast cancer risk. Eur J Cancer Prev 14: 139-142.
12. Bishayee A, (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2: 409-418.
13. Li Y, Kong D, Wang Z, Sarkar FH, (2010) Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res 27: 1027-1041.
14. Selcuklu SD, Donoghue MT, Spillane C, (2009) miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 37: 918-925.
15. Liu J, Zheng M, Tang YL, Liang XH, Yang Q, (2011) MicroRNAs, an active and versatile group in cancers. Int J Oral Sci 3: 165-175.
16. Mocellin S, Pasquali S, Pilati P, (2009) Oncomirs: from tumor biology to molecularly targeted anticancer strategies. Mini Rev Med Chem 9: 70-80.
17. Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, et al. (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8: 529-538.
18. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
19. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, et al. (2012) MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130: 611-621.
20. Si ML, Zhu S, Wu H, Lu Z, Wu F, et al. (2007) miR-21-mediated tumor growth. Oncogene 26: 2799-2803.
21. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359.
22. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658.
23. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, et al. (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128-2136.
24. Qin W, Zhao B, Shi Y, Yao C, Jin L, et al. (2009) BMPRII is a direct target of miR-21. Acta Biochim Biophys Sin (Shanghai) 41: 618-623.
25. Li Y, Li W, Yang Y, Lu Y, He C, et al. (2009) MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 1286: 13-18.
26. Chan JA, Krichevsky AM, Kosik KS, (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033.
27. Ma X, Becker Buscaglia LE, Barker JR, Li Y, (2011) MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 3: 159-166.
28. Delworth M, Nishioka K, Pettaway C, Gutman M, Killion J, et al. (1995) Systemic administration of 4-amidinoindanon-1-(2'-amidino)-hydrazone, a new inhibitor of s-adenosylmethionine decarboxylase, produces cytostasis of human prostate-cancer in athymic nude-mice. Int J Oncol 6: 293-299.
29. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, et al. (1984) Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44: 3522-3529.
30. Kaur T, Mukherjea D, Sheehan K, Jajoo S, Rybak LP, et al. (2011) Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis 2: e180.
31. Jajoo S, Mukherjea D, Pingle S, Sekino Y, Ramkumar V, (2006) Induction of adenosine A1 receptor expression by pertussis toxin via an adenosine 5′-diphosphate ribosylation-independent pathway. J Pharmacol Exp Ther 317: 1-10.
32. Jajoo S, Mukherjea D, Watabe K, Ramkumar V, (2009) Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 11: 1132-1145.
33. Tili E, Michaille JJ, Alder H, Volinia S, Delmas D, et al. (2010) Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem Pharmacol 80: 2057-2065.
34. Mukhopadhyay P, Mukherjee S, Ahsan K, Bagchi A, Pacher P, et al. (2010) Restoration of altered microRNA expression in the ischemic heart with resveratrol. PLoS One 5: e15705.
35. Cai X, Hagedorn CH, Cullen BR, (2004) Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10: 1957-1966.
36. Sayed D, He M, Hong C, Gao S, Rane S, et al. (2010) MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 285: 20281-20290.
37. Li T, Li D, Sha J, Sun P, Huang Y, (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383: 280-285.
38. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, et al. (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69: 7165-7169.
39. Pang Y, Young CY, Yuan H, (2010) MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42: 363-369.
40. Arbuzova A, Schmitz AA, Vergeres G, (2002) Cross-talk unfolded: MARCKS proteins. Biochem J 362: 1-12.
41. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, et al. (2003) The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23: 26-37.
42. Bitomsky N, Bohm M, Klempnauer KH, (2004) Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene 23: 7484-7493.
43. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, et al. (2005) Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 65: 11282-11286.
44. Wei N, Liu SS, Chan KK, Ngan HY, (2012) Tumour suppressive function and modulation of programmed cell death 4 (PDCD4) in ovarian cancer. PLoS One 7: e30311.
45. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, et al. (1998) Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911-915.
46. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL, (1999) Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140: 1984-1989.
47. Torring N, Vinter-Jensen L, Pedersen SB, Sorensen FB, Flyvbjerg A, et al. (1997) Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 158: 222-227.
48. Himpe E, Potikanond S, Verdood P, Kooijman R, (2011) Attenuation of IGF-I receptor signaling inhibits serum-induced proliferation of prostate cancer cells. Growth Horm IGF Res 21: 252-259.
49. Davis BN, Hilyard AC, Lagna G, Hata A, (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56-61.
50. Barrack ER, (1997) TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31: 61-70.
51. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, et al. (2008) miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 378: 492-504.
52. van der Fits L, van Kester MS, Qin Y, Out-Luiting JJ, Smit F, et al. (2011) MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome. J Invest Dermatol 131: 762-768.
53. Kumarswamy R, Volkmann I, Thum T, (2011) Regulation and function of miRNA-21 in health and disease. RNA Biol 8: 706-713.
54. Nakanishi C, Toi M, (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.
55. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, et al. (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127.
56. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr, (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417.
57. Yang CH, Yue J, Fan M, Pfeffer LM, (2010) IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 70: 8108-8116.